On July 23–24, 2026, an FDA advisory panel will decide whether seven peptides — including BPC-157, TB-500, KPV, and Semax — can be legally produced by specialized pharmacies called compounding pharmacies for patients who have prescriptions. The meeting puts the FDA at the heart of a charged debate over drug access, consumer safety, and how strictly regulators should weigh evidence, with Health Secretary Robert F. Kennedy Jr. publicly backing the compounds and calling for an end to what he has called the "FDA's war on public health" (Reuters).

Compounding pharmacies are licensed pharmacies that mix or customize medications for individual patients, rather than mass-producing standardized drugs the way large pharmaceutical manufacturers do. They operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows them to use certain bulk drug substances — essentially raw ingredient powders — if those substances appear on a government-approved list called the 503A Bulks List. The seven peptides under review are being considered for addition to that list (Federal Register).

Peptides are short chains of amino acids, smaller than proteins, that can influence how the body heals, regulates inflammation, and processes pain. The seven under review are promoted for a broad range of conditions: ulcerative colitis, wound healing, inflammatory conditions, obesity, migraines, chronic pain, insomnia, and opioid withdrawal. The FDA's briefing documents, published ahead of the meeting, state there is little evidence supporting the safety or effectiveness of these compounds, citing inadequate human clinical trials and concerns about quality, stability, and consistency (Al Jazeera). The FDA briefing document also lists Emideltide (free base)/Emideltide acetate and Epitalon-related bulk drug substances among those under consideration (FDA).

This meeting partially reverses a 2023 FDA decision. That year, the agency removed 14 peptides from the list compounding pharmacies are permitted to use, citing risks related to immunogenicity (the tendency of a substance to trigger an immune reaction), toxicity, and impurity (Reuters). The current review could loosen that stance — a prospect already moving markets. In April 2026, shares of Hims & Hers Health rose amid expectations the FDA would consider broader access to compounded peptides (Reuters).

Kennedy, who oversees the FDA as Health Secretary, has made peptides central to his broader critique of the agency. He has described what he calls the "aggressive suppression" of psychedelics, peptides, and stem cells, and has stated that he has used peptides personally with "really good effect." He argues that restrictions have pushed consumers into an unregulated grey market — a space where products are sold outside legal channels with no quality oversight (Al Jazeera).

The panel itself has drawn scrutiny. The Pharmacy Compounding Advisory Committee (PCAC), which advises the FDA, has 14 members. According to the Associated Press, seven of those members have ties to businesses or clinics involved in peptide therapies. Among them is Tennessee state senator and pharmacist Bobby Harshbarger, whose family owns a pharmacy that sells compounded medications. His mother, Republican Representative Diana Harshbarger, urged Kennedy last year to loosen FDA restrictions on peptides (Al Jazeera). The Department of Health and Human Services has defended the panel, stating that every member underwent the same ethics review required for FDA advisory committees and that anyone failing to meet federal ethics requirements was removed (Al Jazeera).

The PCAC's recommendations are not binding on the FDA. The committee, established under the Federal Advisory Committee Act, operates as an advisory body whose conclusions inform but do not dictate agency action. FDA advisory committees are either mandated by statute or established at HHS discretion, and each is subject to renewal at two-year intervals unless the charter states otherwise (FDA).

The broader context here is a collision between two regulatory philosophies. On one side is the FDA's evidence-based framework, which requires adequate clinical data before compounds are deemed safe for compounding. The agency's 2023 delisting of 14 peptides was grounded in specific pharmacological concerns — immunogenicity, toxicity, and impurity — that remain unresolved for the compounds under current review. On the other side is Kennedy's posture, which frames restriction itself as a form of harm, arguing that prohibition drives consumers toward unregulated sources with even less oversight. The tension between these positions is sharpened by Kennedy's dual role: he is both the political superior of the FDA and an avowed personal beneficiary of the very substances the agency is evaluating.

The panel's conflict-of-interest questions add another layer. Seven of 14 voting members with financial or professional ties to peptide-related businesses is a ratio that would draw scrutiny in any advisory context. The HHS defense — standard ethics review applied uniformly — is procedurally sound, but it does not address the structural question of whether a panel so heavily populated with compounding-industry stakeholders can render an assessment the public will trust as scientifically independent. The Harshbarger family connection, in which a panel member's mother directly lobbied the Health Secretary on the same issue, gives that concern a specific, traceable thread.

What happens next depends on the FDA's response to whatever the PCAC produces. If the agency adds some or all of the seven substances to the 503A Bulks List, compounding pharmacies operating under Section 503A would gain legal authority to manufacture and dispense these peptides with prescriptions, reopening a market the agency closed in 2023. If the FDA declines to list them, the grey market Kennedy cites as a problem would persist, and the political pressure from HHS would likely continue. Either outcome carries consequences for the compounding pharmacy industry, the telehealth platforms that have built business models around compounded therapeutics, and patients seeking access to compounds the medical literature has not yet fully evaluated.

For anyone tracking this space, the key variables to watch are the specific wording of the PCAC's recommendations, whether the FDA's final determination tracks or diverges from those recommendations, and whether any subsequent listing includes conditions — such as labeling requirements, pharmacy certification standards, or post-market surveillance — that would constrain compounding access even while permitting it. The April 2026 market reaction to the mere prospect of broader access suggests the commercial stakes are substantial, and the political stakes, given Kennedy's positioning, are equally clear.